TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company focused on developing innovative therapeutics that aim to overcome both primary and acquired resistance to cancer immunotherapies. The company leverages its proprietary Immune Fx™ (IFx) technology platform, which harnesses the innate immune system by making tumor cells mimic bacteria to stimulate immune attack. Its lead candidate, IFx-2.0, targets aggressive skin cancers, including Merkel cell carcinoma, and is currently in a Phase 3 clinical trial. Additionally, TuHURA Biosciences develops bi-specific immune modulating antibody drug conjugates (ADCs) and antibody-peptide conjugates (APCs) targeting myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment to prevent immunosuppression and enhance checkpoint inhibitor effectiveness. The company also acquired TBS-2025, a VISTA-inhibiting monoclonal antibody for potential treatment of blood-related cancers such as acute myeloid leukemia. TuHURA’s integrated technologies address major challenges limiting the efficacy of immunotherapies, positioning it as a notable player in advancing cancer treatment modalities.